Drug Trial Radar · NCT06375733
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
51
Planned (sponsor's estimate)
Start
Mar 20, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Genfleet Therapeutics (Shanghai) Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Conditions
- Large B-cell Lymphoma
Interventions
GFH009Drug
administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.
ZanubrutinibDrug
administered at 160mg BID oral; 28-day a cycle until disease progresses.
GFH009Drug
the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.
ZanubrutinibDrug
administered at 160mg BID oral; 28-day a cycle until disease progresses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: adverse events(AEs)Time frame: From Screening (Day -28 to Day-1) to 30 days ±7 days after the last dose, or until the start of a new anti-tumor therapy,assessed up to 32 months
- Phase II: ORRTime frame: From Screening (Day -28 to Day-1) to 30 days ±7 days after the last dose,or until the start of a new anti-tumor therapy, assessed up to 32 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute
Nanning, China · Recruiting
Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.